Global Warfarin Sodium (CAS 129-06-6) Market Size By Type (1mg/Tablet, 2.5mg/Tablet), By Application (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast
Published on: 2024-08-07 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Global Warfarin Sodium (CAS 129-06-6) Market Size By Type (1mg/Tablet, 2.5mg/Tablet), By Application (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast
Warfarin Sodium (CAS 129-06-6) Market Size And Forecast
Warfarin Sodium (CAS 129-06-6) Market size was valued at USD 197.69 Billion in 2024 and is projected to reach USD 283.3 Billion by 2031, growing at a CAGR of 4.60% from 2024 to 2031.
The increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. The Global Warfarin Sodium (CAS 129-06-6) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Warfarin Sodium (CAS 129-06-6) Market Definition
Warfarin Sodium is the sodium salt form of warfarin, with anticoagulant activity. CAS 129-06-6 is a unique numerical identifier of warfarin sodium assigned by the Chemical Abstracts Service. It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin Sodium is categorized into three types1 mg/Tablet, 2.5 mg/Tablet, and 5 mg/Tablet.
It is generally taken by mouth, but can also be used by injection into a vein. Warfarin sodium inhibits vitamin K and vitamin K epoxide reductases, thereby obstructing the cyclic interconversion of vitamin K epoxide to its diminished form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate resting on the N-terminal regions of vitamin K-dependent proteins. The most common side effect is bleeding and less common side effects include areas of tissue damage and purple toes syndrome.
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Global Warfarin Sodium (CAS 129-06-6) Market Overview
Thus, the increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. However, the several side effects of warfarin sodium such as red or brown urine, black or bloody stool, severe headache or stomach pain, joint pain, vomiting, and coughing up blood are hampering the global market growth. Overdose of warfarin sodium also leads to severe blooding or heavier than normal menstrual bleeding, which is also expected to restrict the market growth.
Global Warfarin Sodium (CAS 129-06-6) Market Segmentation Analysis
The Global Warfarin Sodium (CAS 129-06-6) Market Is Segmented On The Basis Of Type, Application, And Geography.
Warfarin Sodium (CAS 129-06-6) Market, By Type
- 1mg/Tablet
- 2.5mg/Tablet
- 5mg/Tablet
Based on Type, the market is segmented into 1mg/Tablet, 2.5mg/Tablet, and 5mg/Tablet. Warfarin, an anticoagulant works by preventing the formation of harmful blood clots. Although it does not dissolve the existing blood clots, it prevents them from growing larger and causing blockages in the blood vessels. It also has a common side effect of Bleeding. Hence it is always advised to consume Warfarin in small amounts. Hence 1mg/Tablets are consumed more and these factors are expected to boost demand for 1mg/Tablets and further propel market growth.
Warfarin Sodium (CAS 129-06-6) Market, By Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies usually stock a larger variety of medications, including more specialized and investigational medications, than would be feasible in the community setting. Pharmacists in hotels are more trained and equipped. Warfarin can interact with several medicines hence expert advice is always needed. These factors are expected to boost demand and further propel market growth.
Warfarin Sodium (CAS 129-06-6) Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the world
On the basis of Geography, the Global Warfarin Sodium (CAS 129-06-6) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Europe market is said to be the Fastest Growing Market for Warfarin Sodium (CAS 129-06-6) because there is the highest awareness of deep vein thrombosis and pulmonary embolism and Warfarin is used to prevent stroke prevention, deep vein thrombosis, and pulmonary embolism. The Asia-Pacific place is predicted to develop because of a lack of awareness right now. With the increase in awareness the market will grow too.
Key Players
The “Global Warfarin Sodium (CAS 129-06-6) Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Key Developments
• In 2021, Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership.
• IN 2018, Qilu ranked top 10 of the Chinese Pharmaceutical Industry in 4 consecutive times.
• Cipla was awarded Company of the year 2021 buy the Business Standard.
Report Scope
REPORT ATTRIBUTES | Details |
---|---|
STUDY PERIOD | 2021-2031 |
BASE YEAR | 2024 |
FORECAST PERIOD | 2024-2031 |
HISTORICAL PERIOD | 2021-2023 |
UNIT | Value (USD Billion) |
KEY COMPANIES PROFILED | Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla. |
Segments Covered |
|
Customization Scope | Free report customization (equivalent up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.